Clinical Study

The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

Table 1

Baseline characteristics of patients populations at treatment of CAMR.

Clinical parameters All patients

Age (years)
Male gender, (%) 13 (72)
BMI (Kg/m2)
Primary renal disease
 cGN, (%) 7 (39)
 HBP, (%) 6 (33)
 DM, (%) 1 (6)
 Unknown, (%) 4 (22)
Dialysis type before KT
 Hemodialysis, (%) 13 (72)
 Peritoneal dialysis, (%) 5 (28)
Dialysis duration, month
Donor type, Living, (%) 11 (61)
Multitransplant History, (%) 2 (11)
Main immunosuppressant
 Cyclosporine, (%) 6 (33)
 Tacrolimus, (%) 12 (67)
Previous acute rejection, (%) 8 (44)
Serum Cr (mg/dL)
MDRD eGFR (mL/min//1.73 m2)
Proteinuria (g/day)
Time posttransplant until diagnosis, month
Time posttreatment, month
HLA mismatch number
HLA-DSA
 Not done, (%) 2 (11)
 Positive, Class I, (%) 2 (11)
 Positive, Class II, (%) 5 (28)
 Negative, (%) 9 (50)

CAMR: chronic antibody mediate rejection; BMI: body mass index; cGN: chronic glomerulonephritis; Cr: creatinine; MDRD eGFR: estimated GFR using the Modification of Diet in Renal Disease Study equation; HLA-DSA: donor specific anti-HLA antibody.